4.3 Article

The association between postprandial urinary C-peptide creatinine ratio and the treatment response to liraglutide: a multi-centre observational study

Journal

DIABETIC MEDICINE
Volume 31, Issue 4, Pages 403-411

Publisher

WILEY
DOI: 10.1111/dme.12367

Keywords

-

Funding

  1. Association of British Clinical Diabetologists (ABCD)
  2. MRC [MR/K005707/1] Funding Source: UKRI
  3. Medical Research Council [MR/K005707/1] Funding Source: researchfish
  4. National Institute for Health Research [NF-SI-0611-10219] Funding Source: researchfish

Ask authors/readers for more resources

Aims The response to glucagon-like peptide1 receptor agonist treatment may be influenced by endogenous beta-cell function. We investigated whether urinary C-peptide creatinine ratio assessed before or during liraglutide treatment was associated with treatment response. Methods A single, outpatient urine sample for urinary C-peptide creatinine ratio was collected 2h after the largest meal of the day among two separate groups: (1) subjects initiating liraglutide (0.6 -> 1.2mg daily) or (2) subjects already treated with liraglutide for 20-32weeks. The associations between pretreatment and on-treatment urinary C-peptide creatinine ratio and HbA(1c) change at 32weeks were assessed using univariate and multivariate analyses (the ratio was logarithm transformed for multivariate analyses). Changes in HbA(1c) according to pretreatment urinary C-peptide creatinine ratio quartiles are shown. Results One hundred and sixteen subjects (70 pretreatment, 46 on treatment) with Type2 diabetes from 10 diabetes centres were studied. In univariate analyses, neither pretreatment nor on-treatment urinary C-peptide creatinine ratio correlated with HbA(1c) change (Spearman rank correlation coefficient, r=-0.17, P=0.17 and r=-0.20, P=0.19, respectively). In multi-linear regression analyses, entering baseline HbA(1c) and log urinary C-peptide creatinine ratio, pretreatment and on-treatment log urinary C-peptide creatinine ratio became significantly associated with HbA(1c) change (P=0.048 and P=0.040, respectively). Mean (sd) HbA(1c) changes from baseline in quartiles1 to 4 of pretreatment urinary C-peptide creatinine ratio were -3 +/- 17mmol/mol (-0.3 +/- 1.6%) (P=0.52), -12 +/- 15mmol/mol (-1.1 +/- 1.4%) (P=0.003), -11 +/- 13mmol/mol (-1.0 +/- 1.2%) (P=0.002) and -12 +/- 17mmol/mol (-1.1 +/- 1.6%) (P=0.016), respectively. Conclusions Postprandial urinary C-peptide creatinine ratios before and during liraglutide treatment were weakly associated with the glycaemic response to treatment. Low pretreatment urinary C-peptide creatinine ratio may be more useful than higher values by predicting poorer glycaemic response.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Endocrinology & Metabolism

Impaired awareness of hypoglycaemia: Prevalence and associated factors before and after FreeStyle Libre use in the Association of British Clinical Diabetologists audit

Beatrice Pieri, Harshal Deshmukh, Emma G. Wilmot, Pratik Choudhary, Najeeb Shah, Robert Gregory, Dennis Barnes, Simon Saunders, Jane Patmore, Chris Walton, Robert E. J. Ryder, Thozhukat Sathyapalan

DIABETES OBESITY & METABOLISM (2023)

Article Genetics & Heredity

Recurrent 17q12 microduplications contribute to renal disease but not diabetes

Stuart Cannon, Rhian Clissold, Kittiya Sukcharoen, Marcus Tuke, Gareth Hawkes, Robin N. Beaumont, Andrew R. Wood, Mark Gilchrist, Andrew T. Hattersley, Richard A. Oram, Kashyap Patel, Caroline Wright, Michael N. Weedon

Summary: 17q12 microdeletion and microduplication syndromes are complex disorders with overlapping phenotypes, including diabetes, renal disease, and neurocognitive traits.

JOURNAL OF MEDICAL GENETICS (2023)

Article Endocrinology & Metabolism

The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis

Katherine G. Young, Andrew P. McGovern, Ines Barroso, Andrew T. Hattersley, Angus G. Jones, Beverley M. Shields, Nicholas J. Thomas, John M. Dennis

Summary: This population-based study demonstrates that HbA(1c) screening in adults aged 40-70 years can reduce the time to diabetes diagnosis by a median of 2.2 years compared with routine clinical care.

DIABETOLOGIA (2023)

Article Medicine, Research & Experimental

Infancy-onset diabetes caused by de-regulated AMPylation of the human endoplasmic reticulum chaperone BiP

Luke A. Perera, Andrew T. Hattersley, Heather P. Harding, Matthew N. Wakeling, Sarah E. Flanagan, Ibrahim Mohsina, Jamal Raza, Alice Gardham, David Ron, Elisa De Franco

Summary: Mutation in the FICD gene leads to dysfunction of the endoplasmic reticulum, resulting in cell loss and diabetes mellitus. The study suggests that regulating the activity of FICD may provide therapeutic benefits for treating related diseases.

EMBO MOLECULAR MEDICINE (2023)

Article Health Care Sciences & Services

Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches

Nicholas J. Thomas, Andrew McGovern, Katherine G. Young, Seth A. Sharp, Michael N. Weedon, Andrew T. Hattersley, John Dennis, Angus G. Jones

Summary: This study aimed to compare the performance of different approaches for classifying insulin-treated diabetes without measured classification biomarkers. The results showed that combining early insulin requirement with a T1D probability model and interview-reported diabetes type achieved the highest accuracy.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2023)

Article Immunology

FOXP3 TSDR Measurement Could Assist Variant Classification and Diagnosis of IPEX Syndrome

Rebecca C. Wyatt, Sven Olek, Elisa De Franco, Bjoern Samans, Kashyap Patel, Jayne Houghton, Steffi Walter, Janika Schulze, Rosa Bacchetta, Andrew T. Hattersley, Sarah E. Flanagan, Matthew B. Johnson

Summary: By studying a large cohort of patients diagnosed with IPEX and using TSDR analysis, it was found that diagnosing IPEX at presentation with isolated diabetes can effectively monitor disease progression and predict the course of the disease. This method can aid in the classification and diagnosis of FOXP3 variants and allow for immune modulatory treatment to be initiated before the onset of severe enteropathy.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

Article Biotechnology & Applied Microbiology

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models

Rosa Lundbye Allesoe, Agnete Troen Lundgaard, Ricardo Hernandez Medina, Alejandro Aguayo-Orozco, Joachim Johansen, Jakob Nybo Nissen, Caroline Brorsson, Gianluca Mazzoni, Lili Niu, Jorge Hernansanz Biel, Valentas Brasas, Henry Webel, Michael Eriksen Benros, Anders Gorm Pedersen, Piotr Jaroslaw Chmura, Ulrik Plesner Jacobsen, Andrea Mari, Robert Koivula, Anubha Mahajan, Ana Vinuela, Juan Fernandez Tajes, Sapna Sharma, Mark Haid, Mun-Gwan Hong, Petra B. Musholt, Federico De Masi, Josef Vogt, Helle Krogh Pedersen, Valborg Gudmundsdottir, Angus Jones, Gwen Kennedy, Jimmy Bell, E. Louise Thomas, Gary Frost, Henrik Thomsen, Elizaveta Hansen, Tue Haldor Hansen, Henrik Vestergaard, Mirthe Muilwijk, Marieke T. Blom, Leen M. T. Hart, Francois Pattou, Violeta Raverdy, Soren Brage, Tarja Kokkola, Alison Heggie, Donna McEvoy, Miranda Mourby, Jane Kaye, Andrew Hattersley, Timothy McDonald, Martin Ridderstrale, Mark Walker, Ian Forgie, Giuseppe N. Giordano, Imre Pavo, Hartmut Ruetten, Oluf Pedersen, Torben Hansen, Emmanouil Dermitzakis, Paul W. Franks, Jochen M. Schwenk, Jerzy Adamski, Mark McCarthy, Ewan Pearson, Karina Banasik, Simon Rasmussen, Soren Brunak

Summary: The application of multiple omics technologies in biomedical cohorts can reveal patient-level disease characteristics and individualized response to treatment. We developed a deep-learning-based framework, MOVE, to integrate and analyze multi-omics data from a cohort of newly diagnosed type 2 diabetes patients. By using in silico perturbations, we identified drug-omics associations in the multi-modal datasets with higher sensitivity than univariate statistical tests.

NATURE BIOTECHNOLOGY (2023)

Article Biochemistry & Molecular Biology

Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study

Beverley M. Shields, Catherine D. Angwin, Maggie H. Shepherd, Nicky Britten, Angus G. Jones, Naveed Sattar, Rury Holman, Ewan R. Pearson, Andrew T. Hattersley

Summary: Patient preference plays a crucial role in medication selection for chronic medical conditions like type 2 diabetes. Balancing potential efficacy and side effects, patient preference can inform treatment decisions based on personal experience with alternative medications. A recent study on type 2 diabetes patients compared three different glucose-lowering drugs and found that allocating therapy based on individual drug preference resulted in better glycemic control and fewer side effects compared to prescribing the overall most preferred drug.

NATURE MEDICINE (2023)

Article Biochemistry & Molecular Biology

Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study

Beverley M. M. Shields, John M. M. Dennis, Catherine D. D. Angwin, Fiona Warren, William E. E. Henley, Andrew J. J. Farmer, Naveed Sattar, Rury R. R. Holman, Angus G. G. Jones, Ewan R. R. Pearson, Andrew T. T. Hattersley

Summary: Precision medicine in type 2 diabetes aims to treat patients based on their clinical characteristics. This study examines the differential drug response in relation to body mass index (BMI) and estimated glomerular filtration rate (eGFR). The findings suggest that in obese patients, thiazolidinediones may be more effective in lowering glucose levels compared to DPP4 inhibitors, while in patients with eGFR of 60-90 ml/min/1.73 m², DPP4 inhibitors may be more effective than SGLT2 inhibitors in lowering glucose levels.

NATURE MEDICINE (2023)

Article Gastroenterology & Hepatology

Neutralising antibody potency against SARS-CoV-2 wild- type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou, James L. Alexander, Simeng Lin, Claire Bewshea, Neil Chanchlani, Rachel Nice, Timothy J. McDonald, Christopher A. Lamb, Shaji Sebastian, Klaartje Kok, Charlie W. Lees, Ailsa L. Hart, Richard C. Pollok, Rosemary J. Boyton, Daniel M. Altmann, Katrina M. Pollock, James R. Goodhand, Nicholas A. Kennedy, Tariq Ahmad, Nick Powell, C. L. A. R. I. T. Y. study investigators CLARITY Study Investigators

Summary: This study aimed to determine the impact of the anti-TNF drug infliximab and the anti-integrin drug vedolizumab on vaccine-induced neutralising antibodies against the omicron variant of SARS-CoV-2. The results showed that patients treated with infliximab had significantly lower antibody levels after three doses of vaccine compared to those treated with vedolizumab, and they also had a higher risk of breakthrough infection.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

Review Public, Environmental & Occupational Health

The phenotype of type 1 diabetes in sub-Saharan Africa

Jean Claude Katte, Timothy J. McDonald, Eugene Sobngwi, Angus G. Jones

Summary: The phenotype of type 1 diabetes in Africa, especially sub-Saharan Africa, is poorly understood. Previous studies have suggested differences in phenotype from the classical form of the disease described in western literature. Accurate diagnosis is challenging due to atypical diabetes forms and limited resources. The age of onset seems to be later in sub-Saharan Africa.

FRONTIERS IN PUBLIC HEALTH (2023)

Correction Biotechnology & Applied Microbiology

Discovery of drug-omics associations in type 2 diabetes with generative deep-learning models (vol 41, pg 399, 2023)

Rosa Lundbye Allesoe, Agnete Troen Lundgaard, Ricardo Hernandez Medina, Alejandro Aguayo-Orozco, Joachim Johansen, Jakob Nybo Nissen, Caroline Brorsson, Gianluca Mazzoni, Lili Niu, Jorge Hernansanz Biel, Cristina Leal Rodriguez, Valentas Brasas, Henry Webel, Michael Eriksen Benros, Anders Gorm Pedersen, Piotr Jaroslaw Chmura, Ulrik Plesner Jacobsen, Andrea Mari, Robert Koivula, Anubha Mahajan, Ana Vinuela, Juan Fernandez Tajes, Sapna Sharma, Mark Haid, Mun-Gwan B. Hong, Petra Musholt, Federico De Masi, Josef Vogt, Helle Krogh Pedersen, Valborg Gudmundsdottir, Angus Jones, Gwen Kennedy, Jimmy Bell, E. Louise Thomas, Gary Frost, Henrik Thomsen, Elizaveta Hansen, Tue Haldor Hansen, Henrik Vestergaard, Mirthe T. Muilwijk, Marieke M. Blom, Leen 't Hart, Francois Pattou, Violeta Raverdy, Soren Brage, Tarja Kokkola, Alison Heggie, Donna McEvoy, Miranda Mourby, Jane Kaye, Andrew Hattersley, Timothy McDonald, Martin Ridderstrale, Mark Walker, Ian N. Forgie, Giuseppe Giordano, Imre Pavo, Hartmut Ruetten, Oluf Pedersen, Torben Hansen, Emmanouil W. Dermitzakis, Paul M. Franks, Jochen Schwenk, Jerzy I. Adamski, Mark McCarthy, Ewan Pearson, Karina Banasik, Simon Rasmussen, Soren Brunak

NATURE BIOTECHNOLOGY (2023)

Editorial Material Medical Laboratory Technology

Laboratory Guidelines Are Needed for Diagnostic Genetic Testing for Monogenic Diabetes

Andrew T. Hattersley

CLINICAL CHEMISTRY (2023)

Article Endocrinology & Metabolism

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Adem Y. Dawed, Andrea Mari, Andrew Brown, Timothy J. McDonald, Lin Li, Shuaicheng Wang, Mun-Gwan Hong, Sapna Sharma, Neil R. Robertson, Anubha Mahajan, Xuan Wang, Mark Walker, Stephen Gough, Leen M. 't Hart, Kaixin Zhou, Ian Forgie, Hartmut Ruetten, Imre Pavo, Pallav Bhatnagar, Angus G. Jones, Ewan R. Pearson, for the D. I. R. E. C. T. consortium DIRECT consortium

Summary: This study identified genetic variants associated with the response to GLP-1 receptor agonist treatment in patients with type 2 diabetes, which provides valuable insights for clinical decision making and personalized medicine.

LANCET DIABETES & ENDOCRINOLOGY (2023)

No Data Available